Table 1.
Patient characteristics
| Characteristics | All | Cachexia* | Noncachexia |
|---|---|---|---|
| Number of patients | 18 | 11 | 7 |
| Median age (range) | 74.5 (70-82) | 74 (70-82) | 76 (70-81) |
| Gender (women:men) | 9:9 | 4:7 | 5:2 |
| ECOG-PS, n (%) | |||
| 0 | 6 (33) | 3 (27) | 3 (43) |
| 1 | 12 (67) | 8 (73) | 4 (57) |
| Stage, n (%) | |||
| III | 1 (6) | 1 (100) | 0 |
| IV | 17 (94) | 10 (59) | 7 (41) |
| Chemotherapy regimen | |||
| Cisplatin + pemetrexed | 3 | 2 | 1 |
| Cisplatin + etoposide | 1 | 1 | 0 |
| Docetaxel | 5 | 3 | 2 |
| Vinorelbine | 2 | 2 | 0 |
| Gefitinib | 4 | 1 | 3 |
| Erlotinib | 3 | 2 | 1 |
| Number of hospitalizations, median (range) | 1 (1-4) | 1 (1-4) | 1 (1-4) |
*Diagnosis of cancer cachexia was based on the International Consensus Criteria.ECOG-PS: Eastern Cooperative Oncology Group-performance status